儿童急性髓系白血病微小残留病最佳阈值:基于TARGET数据库的回顾性队列研究
该回顾性队列研究利用TARGET-AML数据库纳入1205例新发儿童AML患者,比较传统MRD阈值0.1%与更低阈值0.05%在诱导疗程1和2后的预后判别能力。ROC分析确定预测5年EFS的最佳阈值为0.05%,其风险比和净重分类改善均优于0.1%,提示更敏感阈值可能改善风险分层。
要点
- 诱导疗程1和2后,MRD≥0.05%预测5年EFS的AUC分别为0.840和0.854。
- 0.05%阈值首事件HR高于0.1%阈值(疗程1:HR=2.8;疗程2:HR=3.7;均P<0.001)。
- 0.05%阈值净重分类改善显著(疗程1 NRI=0.15,疗程2 NRI=0.18)。
核心结论
- 在既往COG试验治疗的儿童AML中,MRD阈值0.05%较传统0.1%提供更优的预后判别能力。
研究设计与样本
- 回顾性队列研究,数据来自TARGET-AML计划,纳入1205例在COG临床试验中心治疗的新发儿童AML患者,1996年9月至2016年12月入组,中位随访6.2年(范围0.5-20.1年)。
主要发现
- ROC分析确定预测5年EFS的最佳阈值为0.05%,诱导疗程1后AUC为0.840(95%CI[0.76,0.88]),疗程2后AUC为0.854(95%CI[0.78,0.89])。
- 0.05%阈值首事件HR高于0.1%阈值:疗程1后HR=2.8(95%CI[2.3,3.3],P<0.001),疗程2后HR=3.7(95%CI[3.0,4.6],P<0.001)。
- NRI分析显示0.05%阈值显著改善风险分类:疗程1后总体NRI=0.15,疗程2后总体NRI=0.18。
关键数值与推荐
- 传统流式细胞术MRD阳性阈值为0.1%,研究评估更低阈值0.05%在诱导疗程1和2后的预后表现。
- 主要结局为5年无事件生存(EFS),采用Kaplan-Meier生存估计、Cox比例风险模型、ROC曲线和净重分类改善(NRI)分析。
临床怎么用
- 结果支持在未来的临床试验设计中测试0.05%这一更敏感的MRD阈值,以改进风险适配治疗。
局限性
- 回顾性设计使用跨越20年的历史试验数据,可能限制对当代治疗的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Minimal residual disease (MRD) monitoring is a cornerstone of risk stratification in pediatric acute myeloid leukemia (AML), with a threshold of 0.1% conventionally defining positivity by flow cytometry. Advances in flow cytometric technologies, enabling detection of leukemic cells with higher sensitivity and specificity, warrant a reevaluation of whether a lower threshold improves prognostic accuracy. METHODS AND FINDINGS: We conducted a retrospective cohort study using data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET)-AML initiative. The study population comprised 1,205 pediatric patients with de novo AML treated across Children's Oncology Group (COG) clinical trial centers. Patients were enrolled between September 1996 and December 2016, with a median follow-up of 6.2 years (range: 0.5-20.1 years). The primary objective was to compare the prognostic performance of the traditional MRD threshold (≥0.1%) with a lower threshold (≥0.05%) after induction courses 1 and 2. The main outcome measure was 5-year event-free survival (EFS). Analyses included Kaplan-Meier survival estimates, Cox proportional hazards models to calculate hazard ratios (HR) with 95% confidence intervals (CI), receiver operating characteristic (ROC) curves, and net reclassification improvement (NRI). The optimal threshold for predicting 5-year EFS, determined by ROC analysis, was 0.05% after both induction course 1 (AUC: 0.840, 95%CI[0.76,0.88]) and course 2 (AUC: 0.854, 95%CI[0.78,0.89]). The 0.05% threshold demonstrated higher HR for the first event than the 0.1% threshold (after course 1: HR = 2.8, 95%CI[2.3,3.3]; P < 0.001; after course 2: HR = 3.7, 95%CI[3.0,4.6]; P < 0.001). NRI analysis confirmed significant improvement in risk classification with the 0.05% threshold (overall NRI: 0.15 after course 1, 0.18 after course 2). The main limitation of this study is its retrospective design using historical data from trials conducted over 20 years, which may limit generalizability to contemporary treatments. CONCLUSIONS: A lower MRD threshold of 0.05% provides superior prognostic discrimination compared to the conventional 0.1% threshold in pediatric AML treated in previous COG trials. These findings support testing this more sensitive threshold in future clinical trial designs for improved risk-adapted therapy.
引用
- Liao XY, Zheng H, Fang JP, et al. Optimal minimal residual disease threshold in pediatric acute myeloid leukemia: A retrospective cohort study based on the TARGET database. PLoS Med. 2026. PMID: 42102025. doi:10.1371/journal.pmed.1005088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。